A phase III randomized, bouble blind, placebo-controlled trial comparing capecitabine plus sorafenib versus capecitabine plus placebo in the treatment of locally advanced or metastatic HER2-negative breast cancer
José Baselga, MD, PhD (Hospital Universitari Vall d'Hebron, Barcelona)
William J. Gradishar, MD (Robert H. Lurie Comprehensive Cancer Center, Northwestern University)